Intravenous iron: the iatrogenic kick to lose control over oxygen?
Effective erythropoiesis requires both erythropoietin and iron. Regular, intravenous iron supplements represent a standard adjuvant therapy for the treatment of anemia of chronic kidney disease. In this paper, the authors speculate upon potential deleterious effects of intravenous iron on cellular physiology in the setting of the increased oxidant burden of hemodialysis patients.
Deicher
R
R
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse, Wien, Osterreich. robert.deicher@nephro.imed3.akh-wien.ac.at
Hörl
W H
WH
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007049:Iatrogenic Disease; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D018384:Oxidative Stress; D006435:Renal Dialysis
D007501:Iron